Tag: ACS

TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy...

A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September,...

Adrian Banning

Adrian Banning (John Radcliffe Hospital, Oxford, UK) initially wanted to fly a Boeing 747 but, aged nine, decided go into medicine instead. He talks...

Alirocumab receives EC approval in established atherosclerotic cardiovascular disease

The European Commission (EC) has approved the use of alirocumab (Praluent, Sanofi), a PCSK9 inhibitor, in adults with established atherosclerotic cardiovascular disease (ASCVD) to...

Age is a strong predictor of spontaneous myocardial infarction in medically...

Renato D Lopes (Division of Cardiology, Department of Medicine, Duke University School of Medicine, Duke Clinical Research, Durham, USA) and others report in the...